quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:02:34·132d
SECFiling
Merus N.V. logo

SEC Form S-8 POS filed by Merus N.V.

MRUS· Merus N.V.
Health Care
Original source

Companies

  • MRUS
    Merus N.V.
    Health Care

Recent analyst ratings

  • Sep 17UpdateBarclays$112.00
  • Aug 25UpdateAlliance Global Partners$90.00
  • Feb 13UpdatePiper Sandler$84.00
  • Feb 7UpdateWells Fargo$91.00
  • Nov 21UpdateGoldman$73.00
  • Oct 24UpdateUBS$72.00

Related

  • PR71d
    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
  • SEC104d
    SEC Form 15-12G filed by Merus N.V.
  • SEC114d
    Amendment: SEC Form SCHEDULE 13D/A filed by Merus N.V.
  • SEC114d
    Amendment: SEC Form 25-NSE/A filed by Merus N.V.
  • SEC114d
    Merus N.V. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders
  • SEC114d
    Amendment: SEC Form SC 14D9/A filed by Merus N.V.
  • SEC114d
    Amendment: SEC Form SC TO-T/A filed by Merus N.V.
  • INSIDER115d
    Large owner Genmab A/S bought $79,098,068 worth of shares (815,444 units at $97.00) (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022